

**IN THE CLAIMS**

Please amend the claims as follows. This listing replaces all previous versions of the claims in this application.

1-23 (canceled)

24. (new) A method of treating schizophrenia and/or affective psychosis in a subject, comprising administering to the subject a polynucleotide fragment or fragments comprising *SEMCAP3*, *N33*, *GRIK4*, *NPAS3*, *PDE4B* and/or *CDH8* gene(s) or a fragment(s), derivative(s) or homologue(s) thereof.

25. (new) The method according to claim 24 wherein the *SEMCAP3* nucleotide fragment comprises the sequence found in the public database under accession number AF127084 - AF127088, KIAA1095, AB029018, XM\_041363 or BC014432 or the sequence shown in Figure 3.

26. (new) The method according to claim 24 wherein the *N33* polynucleotide fragment comprises the sequence found in the public database under accession number U42349 or BAC RP11-23;14 or the sequences shown in Figures 6 or 7.

27. (new) The method according to claim 24 wherein the *GRIK4* polynucleotide fragment comprises the sequence found in the public database under accession number NM\_014619 or the sequences shown in Figures 10 or 16.

28. (new) The method according to claim 24 wherein the *NPAS3* polynucleotide fragment comprises the sequence found in the public database under accession number AB054575 or AF164438 or the sequences shown in Figures 18 or 20.

29. (new) The method according to claim 24 wherein the PDE4B polynucleotide fragment comprises the sequence as shown in Figures 25, 27 or 29.

30. (new) The method according to claim 24 wherein the CDH8 polynucleotide comprises the sequence found in the public database under accession number L34060, AB035305, NM\_001796, AB010436, AB010437, BAC CTC-420A11 or AC040161 or as shown in Figure 35.

31. (new) A method of treating schizophrenia and/or affective psychosis in a subject, comprising administering to the subject a polypeptide fragment or fragments comprising *SEMCAP3*, *N33*, *GRIK4*, *NPAS3*, *PDE4B* and/or *CDH8* gene(s) or a fragment(s), derivative(s) or homologue(s) thereof.

32. (new) The method according to claim 31 wherein the SEMCAP3 polypeptide fragment comprises the sequence found in the public database under accession number AAF22131, AAF22132 or XP\_041363, or as shown in Figure 4.

33. (new) The method according to claim 31 wherein the *N33* polypeptide fragment comprises the sequence found in the public database under accession number Q13454 or as shown in Figures 6 or 7.

34. (new) The method according to claim 31 wherein the GRIK4 polypeptide fragment comprises the sequence found in the public database under accession number NM\_014619, or as shown in Figures 11 and 17.

35. (new) The method according to claim 31 wherein the PDE4B polypeptide fragment comprises the sequence as shown in Figures 26, 28 or 30.

36. (new) The method according to claim 31 wherein the CDH8 polypeptide fragment comprises the sequence found in the public database under accession number NP\_001787 or as shown in Figure 36.

37. (new) The method according to claim 31 wherein the polynucleotide fragment or polypeptide fragment consists essentially of the identified sequences.

38. (new) A method of diagnosing schizophrenia and/or affective psychosis or susceptibility to schizophrenia and/or affective psychosis in an individual, wherein the method comprises determining if *SEMCAP3*, *N33*, *GRIK4*, *NPAS3*, *PDE4B* and/or *CDH8* gene(s) in the individual has/have been disrupted by a mutation or chromosomal rearrangement.

39. (new) The method according to claim 38 wherein any disruption is determined by detecting a relative level of mRNA expressed by the/said *SEMCAP3*, *N33*, *GRIK4*, *NPAS3*, *PDE4B* and/or *CDH8* gene(s).

40. (new) The method according to claim 38 wherein a level of the/said *SEMCAP3*, *N33*, *GRIK4*, *NPAS3*, *PDE4B* and/or *CDH8* gene products are detected by an immunological technique.

41. (new) The method according to claim 40 wherein an antibody or antibodies specific for the/said gene(s) is used to detect said gene product(s).

42. (new) A method for the treatment of schizophrenia and/or affective psychosis, comprising administering an antibody or antibodies specific for *SEMCAP3*, *N33*, *GRIK4*, *NPAS2*, *PDE4B* and/or *CDH8*.

43. (new) An animal model for psychiatric disorders wherein the animal model has been generated by specifically disrupting expression of the/said *SEMCAP3*, *N33*, *GRIK4*, *NPAS2*, *PDE4B* and/or *CDH8* gene(s).

44. (new) An animal model for psychiatric disorder wherein the animal model has been generated by specifically upregulating expression of the/said *SEMCAP3*, *N33*, *GRIK4*, *NPAS2*, *PDE4B* and/or *CDH8* gene(s).

45. (new) A method for identifying ligands for *SEMCAP3*, *N33*, *GRIK4*, *NPAS2*, *PDE4B* and/or *CDH8* gene(s) products, said method comprising the steps of:

- a) introducing into a suitable host cell a polynucleotide fragment according to the invention;
- b) culturing cells under conditions to allow expression of the polynucleotide fragment;
- c) optionally isolating the expression product;
- d) bringing the expression product (or the host cell from step b)) into contact with potential ligands which will possibly bind to the protein encoded by said polynucleotide fragment from step a);
- e) establishing whether a ligand has bound to the expressed protein; and
- f) optionally isolating and identifying the ligand.